Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Clearside Biomedical

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Clearside Biomedical: Q1 Earnings Insights

Clearside Biomedical (NASDAQ:CLSD) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Why Clearside Biomedical Shares Are Surging Today

Clearside Biomedical Inc (NASDAQ: CLSD) shares are trading higher Friday after the company reported better-than-expected fourth-quarter financial results.

Benzinga's After-Hours Movers & News: DocuSign, Clearside Biomedical And More

Benzinga's “After-Hours Movers & News” highlights the biggest movers of the day. The information on the price action is collected using Benzinga Pro's Movers tool. Benzinga Pro users can cross-reference the Movers tool with the Benzinga Pro News tool to identify potential news catalysts moving stocks.

Recap: Clearside Biomedical Q4 Earnings

Clearside Biomedical (NASDAQ:CLSD) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

inkl

Read news from The Economist, FT, and more,
with one subscription

Organisations

European Commission

Activision Blizzard

Palo Alto Networks

TakeTwo Interactive

Rigetti Computing

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Sickle Cell Disease

Ulcerative Colitis

Macular Degeneration

Amyotrophic lateral sclerosis

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

121,352 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play